Aptevo's AML Drug Mipletamig Achieves 81% Remission, Outperforms Benchmark in Phase 1b Trial
APVO sits 44% above its 52-week low of $3.8 on light trading volume (0.3× avg).
Summary
Aptevo Therapeutics announced highly positive Phase 1b clinical results for its lead drug candidate, mipletamig, in frontline acute myeloid leukemia (AML). The trial demonstrated an 87% clinical benefit rate and an 81% remission rate (CR/CRi) across 31 evaluable patients, substantially outperforming the historical benchmark of 66.4% CR/CRi from the VIALE-A trial. This significant positive data is crucial for Aptevo, especially following its recent 10-K filing which highlighted substantial doubt about its ability to continue as a going concern. The strong efficacy and favorable safety profile could be a pivotal catalyst, potentially attracting investor interest and improving the company's prospects for future financing. Investors should watch for the completion of the Phase 1b trial and the selection of the recommended Phase 2 dose, both expected in 2026.
At the time of this announcement, APVO was trading at $5.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $3.80 to $258.01. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Access Newswire.